Such a busy pharma world and so little time to keep up, yes? Like you, we always poke around for items of interest, and so we thought we would point out a few you may enjoy from the past week. Think of it as a little bit of catching up. Meanwhile, we hope your weekend is enjoyable and look forward to seeing you again tomorrow…

The droll Jim Edwards points out that Sanofi-Aventis has become the latest drugmaker to get into the online video game business, or advergames. This one is for the ubiquitous Ambien Cr sleeping pill, and the game is called “Silence Your Rooster.” You can check it out here.

By striking a deal to fill certain generics for free as part of a trial with Caterpillar, Wal-Mart is subtly undermining the economic model used so well by pharmacy benefit managers, according to Adam Fein. For now, the deal amounts to an alternative channel but Adam posits that the barriers to market exclusivity for brand-name meds will eventually fall.

Another installment of The Ongoing Adventures of Alan Schatzberg, the Stanford University psychiatry department chair who was accused by a Senate committee of failing to properly disclose industry-funded research, comes to us by way of ClinPsyc, which discusses an ‘experimercial’ that involved publishing the same data about Lilly’s Cymbalta med in two different journals.